PellePharm is a biotechnology company that focuses on developing treatments for rare dermatological diseases, specifically Gorlin Syndrome and Basal Cell Carcinomas (BCCs). The company operates in the biopharmaceutical market and primarily serves patients suffering from these conditions. PellePharm's core product is patidegib, an investigational topical treatment aimed at reducing the tumor burden in patients with Gorlin Syndrome and BCCs. The company collaborates with organizations like the Gorlin Syndrome Alliance, The Gorlin Syndrome Group, and LEO Pharma to advance its research and development efforts.

PellePharm's business model revolves around the development and eventual commercialization of patidegib. The company aims to generate revenue through the sale of this treatment once it receives regulatory approval. Currently, there are no FDA-approved drugs for Gorlin Syndrome, making surgery the standard of care. PellePharm's innovative approach targets the underlying genetic defects, offering a potentially transformative solution for patients.

Keywords: biotechnology, dermatological diseases, Gorlin Syndrome, Basal Cell Carcinomas, patidegib, topical treatment, tumor burden, rare diseases, biopharmaceutical, clinical trials.